|Articles|May 1, 2004
FDA gives nod; Hylaform joins ranks of fillers
Santa Barbara, Calif. -- The U.S. Food and Drug Administration late last month granted approval for Inamed Corp.'s Hylaform (Hylan-B gel). The hyaluronic-acid-based dermal filler is indicated for injection into the deep dermis for correction of moderate-to-severe facial wrinkles and folds. The move, while expected, adds a few wrinkles of its own to the growing U.S. market for dermal fillers.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Articles
- Unlocking Skin's Potential from the Inside Out with Glutathione
September 16th 2025
- The Aesthetic Edge: September 2025
September 16th 2025
- The Science Behind a Topical Glutathione Delivery System
September 15th 2025
- Clinical Trials Support New Retinal Formulation Tolerability
September 10th 2025
- Obagi Medical Expands Into Fillers Following FDA Approval
September 10th 2025
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times - Dermatology News and Clinical Insights
1
Beyond the Rash: What Dermatologists Need to Know About the World of Infectious Diseases
2
Douglas DiRuggiero, DMSc, MHS, PA-C, on the Evolving Landscape of Dermatologic Care
3
Nail Pathology in Clinical Practice with Phoebe Rich, MD
4
Adapting to the Age of AI in Clinical Dermatology
5